Medtronic Hits Ten-Quarter Growth Peak in Q3 Fiscal 2026, Signaling Resurgence in MedTech SectorMedtronic (
NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for its fiscal third quarter of 2026, marking a significant turning point for the medical technology giant. The results, released on February 17, 2026, surpassed analyst expectations and highlighted a robust recovery in elective procedure volumes and a
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs DataAs the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector SPDR Fund (NYSE Arca: XLV) posted a robust 1.1% advance this week, standing in stark contrast
Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 MomentumToday’s Date: February 17, 2026 Introduction Medtronic plc (
NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall Street as a stable but slow-moving conglomerate, hampered by its own scale and a fragmented organizational structure. However, the narrative has shifted dramatically in early [...]
The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra AcquisitionIn a move that has sent shockwaves through the medical technology sector, Boston Scientific (
NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (
NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (
NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
Stryker declares an $0.88 per share quarterly dividendPortage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (
NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing ChallengesA stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms RaceIn a move that has sent shockwaves through the healthcare sector, Boston Scientific (
NYSE:BSX) has announced a definitive agreement to acquire Penumbra (
NYSE:PEN) for approximately $14.5 billion. The deal, announced in mid-January and currently the talk of Wall Street as we move into February 2026, marks one
Stryker’s (NYSE:SYK) Q4 CY2025 Sales Top EstimatesMedical technology company Stryker (
NYSE:SYK) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.4% year on year to $7.17 billion. Its non-GAAP profit of $4.47 per share was 1.7% above analysts’ consensus estimates.
Stryker reports 2025 operating results and 2026 outlookPortage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (
NYSE:SYK) reported operating results for the fourth quarter and full year of 2025:
Boston Scientific to Acquire Penumbra for $14.5 Billion in Massive MedTech ConsolidationMARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (
NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (
NYSE: PEN) for an enterprise value of approximately $14.5 billion. The deal, representing Boston Scientific’s largest acquisition in over
What To Expect From Stryker’s (SYK) Q4 EarningsMedical technology company Stryker (
NYSE:SYK) will be reporting results this Thursday after market close. Here’s what to expect.
The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech GiantsIn a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (
NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (
NYSE: PEN) for approximately $14.5 billion. The deal represents one of the most significant consolidations in the history of the medical
2 Cash-Producing Stocks to Consider Right Now and 1 Facing HeadwindsWhile strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
1 Healthcare Stock Worth Your Attention and 2 We AvoidHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately
as healthcare stocks have returned 21.1% over the past six months, topping the S&P 500 by 10.6 percentage points.
The Thrombectomy Titan: Boston Scientific Shakes MedTech with $14.5 Billion Penumbra AcquisitionMARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (
NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (
NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&AAs 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to ReboundFor the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a resilient tech economy, healthcare investors were left nursing a "double-digit hangover." In 2024,
Healthcare Bellwether Braces for Impact: UnitedHealth Group’s High-Stakes Q4 Outlook Signals a Sector-Wide ResetAs the 44th Annual J.P. Morgan Healthcare Conference kicked off this week in San Francisco, all eyes turned to UnitedHealth Group (
NYSE:UNH), the diversified healthcare giant that serves as the primary barometer for the multi-trillion-dollar U.S. medical sector. On January 12, 2026, the company issued a critical
Medtronic (MDT) Deep-Dive: Can the MedTech Giant Outpace the Market in 2026?Date: January 9, 2026 Introduction As the global healthcare landscape undergoes a seismic shift toward personalized medicine and AI-integrated care, Medtronic plc (
NYSE: MDT) stands at a critical juncture. Once viewed as a reliable but sluggish dividend aristocrat, the world’s largest standalone medical technology firm has spent the last 24 months aggressively shedding its "legacy" [...]
1 Oversold Stock Primed to Rebound and 2 That UnderwhelmRock-bottom prices don't always mean rock-bottom businesses.
The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?
Stryker (SYK) Stock Trades Up, Here Is WhyShares of medical technology company Stryker (
NYSE:SYK) jumped 4.1% in the afternoon session after analyst firm Raymond James upgraded the stock to "Outperform" from "Market Perform" and set a $418 price target.
